Your cart is ready — click here to view your products.

CJC-1295 NO DAC (5mg)

CJC-1295 NO DAC (Mod GRF 1-29) is commonly utilised in endocrine, neuroregulatory and growth hormone signalling models.
  • purity_percentage Icon 99% Purity
$82
Description
 

CJC-1295 NO DAC (Mod GRF 1-29) (5mg)
GHRH Analog for Growth Hormone Pulse and Endocrine Research

CJC-1295 NO DAC (Mod GRF 1-29) (5mg) is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), specifically engineered for short-duration studies of growth hormone (GH) pulsatility and endocrine signaling. Also known as Modified GRF 1-29, this peptide omits the drug affinity complex (DAC) to preserve natural, physiologic GH release patterns in research settings.

Product Overview
This 5mg vial of lyophilized CJC-1295 NO DAC is manufactured at >99% purity and is widely used in in vitro models analyzing hypothalamic-pituitary activity, GH feedback loops, and pituitary responsiveness. Its shorter half-life offers researchers precise control over hormone study timing and receptor activation periods.

Key Research Attributes:

  • Short-Acting GHRH Analog: Modified for stability without DAC, enabling study of natural GH pulses without extended stimulation.
  • GH Secretion and Pituitary Study: Used in controlled experiments to analyze pulsatile GH release and downstream signaling.
  • Endocrine Regulation Models: Supports investigation of hypothalamic-pituitary-adrenal (HPA) axis function and receptor activation feedback.
  • Research-Grade Purity: Lyophilized for stability and consistent performance in endocrine research applications.


Applications in Scientific Research

  • Growth hormone pulsatility and feedback loop studies
  • GH-releasing hormone receptor activity experiments
  • Endocrine axis modulation models
  • Comparative analysis with CJC-1295 DAC and other GHRH analogs
  • In vitro pituitary cell activation and hormone release studies

Format and Storage
Form: Lyophilized powder
Purity: >99%
Storage: Store at -20°C in a sealed container
Reconstitution: Reconstitute with sterile bacteriostatic water in lab conditions

Disclaimer: CJC-1295 NO DAC (Mod GRF 1-29) (5mg) is provided for in vitro scientific research use only. It is not for human or veterinary use. Research must adhere to institutional and legal requirements.



Chemical Makeup

Molecular Formula

  • CJC-1295 NO DAC: C152H252N44O42

Molecular Weight

  • CJC-1295 NO DAC: 3367.9 g/mol

Sequence

  • CJC-1295 NO DAC: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2

Other Known Titles

  • CJC-1295 NO DAC: Modified GRF 1-29, CJC-1295 w/o DAC, Mod GRF (1-29)
 

CJC-1295 NO DAC (Mod GRF 1-29) (5mg) is intended strictly for laboratory and research use. Please review our Terms and Conditions before purchase.

More Information
Purity Percentage 99% Purity
Volume 5MG
Bought This Week 15
New No
Sale No
Research

CJC-1295 (No DAC): Effects, Benefits, and Side Effects

CJC-1295 without Drug Affinity Complex, also known as Modified GRF 1-29, is a short-acting growth hormone releasing hormone analog studied for its ability to promote natural pulsatile GH secretion. Its shorter half-life makes it useful in research models exploring physiological GH rhythms, muscle growth, fat metabolism, recovery, and endocrine function. The following sources discuss mechanisms, benefits, risks, and research applications.

  • •
    “CJC-1295 Peptide Guide – Benefits, Effects, Dosage, Side Effects”
    Reviews potential benefits including lean mass support, fat loss, and synergy with other GHRP compounds.
    Read more
  • •
    “CJC-1295 Side Effects, Complications, and Risk Profile”
    Summarises observed side effects such as injection site irritation, water retention, and fatigue.
    Read more
  • •
    “CJC-1295 With and Without DAC: Complete Guide”
    Compares pharmacokinetics, half-life, pulsatility, and effectiveness in different research applications.
    Read more
  • •
    “CJC-1295 Research Reviews, Clinical Trials, and Safety”
    Covers trial findings on GH elevation, IGF-1 signalling, and long-term tolerability in controlled environments.
    Read more
  • •
    “Guide to CJC-1295: Efficiency and Proper Use”
    Explores dosing concepts, GH response curves, and safety considerations.
    Read more
  • •
    “CJC-1295 DAC vs No DAC: Understanding the Differences”
    Examines half-life extension, receptor affinity, and differences in physiological GH release patterns.
    Read more
  • •
    “CJC-1295: Benefits, Dosage, Side Effects & Scientific Research”
    Outlines metabolic effects, appetite modulation, and GH/IGF-1 dynamics from experimental use.
    Read more
  • •
    “CJC-1295 Side Effects: What You Need to Know”
    Reviews reported adverse effects including flushing, dizziness, and temporary temperature increase.
    Read more
  • •
    “CJC-1295 DAC vs No DAC | What’s the Difference?”
    Breaks down distinctions in stability, GH peak profiles, and pairing strategies.
    Read more
  • •
    “CJC-1295 Benefits and Research Applications”
    Summarises modelling applications in muscle repair, metabolic studies, and endocrine signalling.
    Read more